Potassium channels and pain:: present realities and future opportunities

被引:203
|
作者
Ocaña, M [1 ]
Cendán, CM [1 ]
Cobos, EJ [1 ]
Entrena, JM [1 ]
Baeyens, JM [1 ]
机构
[1] Univ Granada, Sch Med, Dept Pharmacol & Neurosci Inst, E-18012 Granada, Spain
关键词
K+ channels; antinociception; G-protein-coupled receptor; opioid; nonsteroidal antiinflammatory drugs; tricyclic antidepressant;
D O I
10.1016/j.ejphar.2004.07.026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Four families of potassium channels with different structures, functional characteristics and pharmacological sensitivity, are distinguished in neurons: voltage-gated (K-v), calcium-activated (K-ca), inward rectifier (K-ir) and two-pore (K-2P) K+ channels. During the last 15 years, numerous studies have demonstrated that the opening of some of these K+ channels plays an important role in the antinociception induced by agonists of many G-protein-coupled receptors (alpha(2)-adrenoceptors, opioid, GABA(B), muscarinic M-2, adenosine A(1), serotonin 5-HT1A and cannabinoid receptors), as well as by other antinociceptive drugs (nonsteroidal antiinflammatory drugs [NSAIDs], tricyclic antidepressants, etc.) and natural products. Several specific types of K+ channels are involved in antinociception. The most widely studied are the ATP-sensitive K+ channels (K-ATP), members of the K-ir family, which participate in the antinociception induced by many drugs that activate them in both the central and the peripheral nervous system. The opening of G-protein-regulated inwardly rectifying K+ channels (GIRK or K(ir)3), K(v)1.1 and two types of K-Ca channels, the small- and large-conductance calcium-activated K+ channels (SK and BK channels, respectively), also play a role in the antinociceptive effect of different drugs and natural products. Recently, drugs that open K+ channels by direct activation (such as openers of neuronal K(v)7 and K-ATP channels) have been shown to produce antinociception in models of acute and chronic pain, which suggests that other neuronal K+ channels (e.g. K(v)1.4 channels) may represent an interesting target for the development of new K+ channel openers with antinociceptive effects. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:203 / 219
页数:17
相关论文
共 50 条
  • [31] Our Future Selves: Unprecedented Opportunities
    Lewis, Carole B.
    PHYSICAL THERAPY, 2016, 96 (10): : 1493 - 1502
  • [32] Decreased abundance of TRESK two-pore domain potassium channels in sensory neurons underlies the pain associated with bone metastasis
    Yang, Yue
    Li, Song
    Jin, Zi-Run
    Jing, Hong-Bo
    Zhao, Hong-Yan
    Liu, Bo-Heng
    Liang, Ya-Jing
    Liu, Ling-Yu
    Cai, Jie
    Wan, You
    Xing, Guo-Gang
    SCIENCE SIGNALING, 2018, 11 (552)
  • [33] Pharmacotherapy of opioids: Present and future developments
    Meert, TF
    PHARMACY WORLD & SCIENCE, 1996, 18 (01): : 1 - 15
  • [34] Levorphanol use: past, present and future
    Gudin, Jeffrey
    Fudin, Jeffrey
    Nalamachu, Srinivas
    POSTGRADUATE MEDICINE, 2016, 128 (01) : 46 - 53
  • [35] Present and Future of Pharmacological Management for Acute Moderate-to-Severe Postoperative, Traumatic, or Musculoskeletal Pain in Europe: A Narrative Review
    Viscusi, Eugene R.
    Epelde, Francisco
    Ruiz, Luis Javier Roca
    Trillo-Calvo, Eva
    PAIN AND THERAPY, 2024, 13 (06) : 1351 - 1376
  • [36] KCNQ potassium channels in sensory system and neural circuits
    Wang, Jing-jing
    Li, Yang
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (01) : 25 - 33
  • [37] ATP-Sensitive Potassium Channels in Health and Disease
    Clark, Rebecca
    Proks, Peter
    ISLETS OF LANGERHANS, 2010, 654 : 165 - 192
  • [38] The Effects of Potassium Channels in Human Internal Mammary Artery
    Afsar, Selim
    Hemsinli, Dogus
    Ozyazgan, Sibel
    Akkan, Ahmet Gokhan
    Arslan, Caner
    PHARMACOLOGY, 2016, 97 (1-2) : 72 - 77
  • [39] Kir2.1 potassium channels and corneal epithelia
    Rae, JL
    Shepard, AR
    CURRENT EYE RESEARCH, 2000, 20 (02) : 144 - 152
  • [40] Targeting Kv7 Potassium Channels for Epilepsy
    Perucca, Emilio
    Taglialatela, Maurizio
    CNS DRUGS, 2025, 39 (03) : 263 - 288